MPDL3280A

MPDL3280A is an investigational treatment for non-small cell lung cancer.

MPDL3280A Overview

Reviewed: February 3, 2015
Updated: 

MPDL3280A is an investigational treatment for non-small cell lung cancer.

MPDL3280A belongs to a group of drugs called monoclonal antibodies. These work by interfering with a protein called PD-L1 and therefore attacks the tumor cells and helps the body's immune system fight cancer cells.

MPDL3280A is being studied by Roche.

In 2014, the US FDA granted the first breakthrough therapy designation for MPDL3280A in metastatic bladder cancer.

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

Manufacturer

Back to Top
Contributors

All RxWiki content including health news, medication pages, and condition pages published prior to February 2023, was written and maintained by on-staff pharmacists. Please be advised that this content is no longer actively maintained and may now contain outdated information. If you have any questions regarding previously published content, please contact support@rxwiki.com.

References
Roche’s NSCLC therapy MPDL3280A gets FDA breakthrough therapy status.